Trethera
  • Home
  • About Us
  • Technology
  • Pipeline
  • Media
    • News
    • Publications
  • Contact
  • Menu

News

Globally Recognized Expert in Rare Neurologic Diseases, Dr. Michael Levy, Joins Trethera Scientific Advisory Board

6th September 2023/in News /by Trethera

Los Angeles, September 5, 2023 — Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced today the appointment of Michael Levy, MD, PhD, to its Scientific Advisory Board.  Dr. Levy will have a particular focus on evaluating the clinical development […]

Read more
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png 0 0 Trethera https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png Trethera2023-09-06 17:29:112023-09-06 17:29:12Globally Recognized Expert in Rare Neurologic Diseases, Dr. Michael Levy, Joins Trethera Scientific Advisory Board

Trethera Receives NIH Grant for Preclinical Development in the Pediatric Neurologic Disease Acute Disseminated Encephalomyelitis

14th August 2023/in Events, News /by Trethera

Los Angeles, August 14, 2023 — Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced today that it was awarded a $600,000 Small Business Technology Transfer (STTR) grant from the National Institute of Allergy and Infectious Diseases (NIAID).   Trethera’s first-in-class […]

Read more
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png 0 0 Trethera https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png Trethera2023-08-14 20:33:002023-09-06 20:33:47Trethera Receives NIH Grant for Preclinical Development in the Pediatric Neurologic Disease Acute Disseminated Encephalomyelitis

Trethera Receives Grant from National Institute of Allergy and Infectious Diseases for the Advancement of TRE-515 in Lupus

12th July 2023/in News /by Trethera

Los Angeles, June 27, 2023 — Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced today that it was awarded a $0.6M Small Business Technology Transfer (STTR) grant from the National Institute for Allergy and Infectious Diseases (NIAID).  The grant […]

Read more
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png 0 0 Trethera https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png Trethera2023-07-12 23:13:242023-07-12 23:21:02Trethera Receives Grant from National Institute of Allergy and Infectious Diseases for the Advancement of TRE-515 in Lupus

Trethera Receives $2 Million National Cancer Institute Grant for Advancement of Clinically Relevant Biomarkers in Phase 1 Trial 

1st June 2023/in News /by Trethera

Los Angeles, May 30, 2023 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced today that it was awarded a $2 million Small Business Innovative Research (“SBIR”) grant from the National Cancer Institute (“NCI”).  The grant will fund additional patient […]

Read more
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png 0 0 Trethera https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png Trethera2023-06-01 00:39:182023-06-01 00:45:31Trethera Receives $2 Million National Cancer Institute Grant for Advancement of Clinically Relevant Biomarkers in Phase 1 Trial 

Dose Escalation Portion of Phase 1 Solid Tumors Trial Produces Favorable Results in Heavily Pretreated Solid Tumor Patients

17th March 2023/in News /by Trethera

Los Angeles, March 15, 2023 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, received a unanimous recommendation from the independent safety review committee (“SRC”) to continue clinical trial advancement of Trethera’s lead development asset, TRE-515, its first-in-class deoxycytidine […]

Read more
https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png 0 0 Trethera https://www.trethera.com/wp-content/uploads/2015/12/trethera_logo-wo.png Trethera2023-03-17 15:06:112023-03-17 18:59:26Dose Escalation Portion of Phase 1 Solid Tumors Trial Produces Favorable Results in Heavily Pretreated Solid Tumor Patients
Page 1 of 6123›»